Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops
Published on May 16, 2025
NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analog).